Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma.

cost-effectiveness cost-utility personalised dosimetry tailored treatment trans-arterial radioembolisation

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 14 04 2022
accepted: 28 07 2022
entrez: 15 9 2022
pubmed: 16 9 2022
medline: 16 9 2022
Statut: epublish

Résumé

To perform a cost-effectiveness analysis (CEA) comparing personalised dosimetry with standard dosimetry in the context of selective internal radiation therapy (SIRT) with TheraSphere for the management of adult patients with locally advanced hepatocellular carcinoma (HCC) from the Italian Healthcare Service perspective. A partition survival model was developed to project costs and the quality-adjusted life years (QALYs) over a lifetime horizon. Clinical inputs were retrieved from a published randomised controlled trial. Health resource utilisation inputs were extracted from the questionnaires administered to clinicians in three oncology centres in Italy, respectively. Cost parameters were based on Italian official tariffs. Over a lifetime horizon, the model estimated the average QALYs of 1.292 and 0.578, respectively, for patients undergoing personalised and standard dosimetry approaches. The estimated mean costs per patient were €23,487 and €19,877, respectively. The incremental cost-utility ratio (ICUR) of personalised versus standard dosimetry approaches was €5,056/QALY. Personalised dosimetry may be considered a cost-effective option compared to standard dosimetry for patients undergoing SIRT for HCC in Italy. These findings provide evidence for clinicians and payers on the value of personalised dosimetry as a treatment option for patients with HCC.

Identifiants

pubmed: 36106105
doi: 10.3389/fonc.2022.920073
pmc: PMC9464985
doi:

Types de publication

Journal Article

Langues

eng

Pagination

920073

Informations de copyright

Copyright © 2022 Rognoni, Barcellona, Bargellini, Bavetta, Bellò, Brunetto, Carucci, Cioni, Crocetti, D’Amato, D’Amico, Deagostini, Deandreis, De Simone, Doriguzzi, Finessi, Fonio, Grimaldi, Ialuna, Lagattuta, Masi, Moreci, Scalisi, Virdone and Tarricone.

Déclaration de conflit d'intérêts

The authors declare that this study received funding from Confindustria Dispositivi Medici Servizi Srl. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

Références

J Manag Care Spec Pharm. 2018 Jun;24(6):514-523
pubmed: 29799329
BMJ. 2001 Mar 3;322(7285):517-9
pubmed: 11230064
Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):810-21
pubmed: 12095546
J Gastrointest Oncol. 2021 Apr;12(2):639-657
pubmed: 34012656
Asia Pac J Public Health. 2016 Jan;28(1):15-25
pubmed: 26512030
Nucl Med Biol. 2018 Apr;59:22-28
pubmed: 29448165
Oncologist. 2018 Feb;23(2):225-233
pubmed: 29021380
Adv Ther. 2020 May;37(5):2116-2126
pubmed: 32193809
PLoS One. 2020 Jan 16;15(1):e0226196
pubmed: 31945065
Health Policy. 2021 May;125(5):602-608
pubmed: 33820679
Gac Sanit. 2014 Jan-Feb;28(1):48-54
pubmed: 24309522
Immunotherapy. 2020 Oct;12(14):1067-1075
pubmed: 32811247
Eur Respir Rev. 2016 Sep;25(141):259-65
pubmed: 27581825
Rev Esp Cardiol (Engl Ed). 2019 May;72(5):398-406
pubmed: 31007166
J Nucl Med. 2015 Mar;56(3):339-46
pubmed: 25678490
Health Econ. 2017 Feb;26 Suppl 1:70-92
pubmed: 28139085
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255
pubmed: 30285213
J Clin Oncol. 2000 Jun;18(11):2210-8
pubmed: 10829040
Eur J Health Econ. 2020 Feb;21(1):153-164
pubmed: 31541309
Int J Technol Assess Health Care. 2021 Apr 26;37(1):e62
pubmed: 33896433
Front Public Health. 2021 Jan 08;8:612410
pubmed: 33490024
Health Econ. 2017 Feb;26 Suppl 1:5-12
pubmed: 28139084
Hepatology. 2013 Mar;57(3):1046-54
pubmed: 23299720
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Clin Ther. 2019 Nov;41(11):2308-2320.e11
pubmed: 31607559
Value Health Reg Issues. 2016 May;9:67-71
pubmed: 27881263
Value Health. 2017 Mar;20(3):336-344
pubmed: 28292478
Value Health. 2020 Dec;23(12):1613-1621
pubmed: 33248517
J Nucl Med. 2012 Feb;53(2):255-63
pubmed: 22302962
Value Health. 2013 Mar-Apr;16(2):418-25
pubmed: 23538194
Value Health. 2013 Mar-Apr;16(2):231-50
pubmed: 23538175
Am J Manag Care. 2020 Oct;26(10 Suppl):S220-S226
pubmed: 33052639
Clin Gastroenterol Hepatol. 2018 Sep;16(9):1503-1510.e3
pubmed: 29609068
Pharmacoecon Open. 2019 Sep;3(3):377-390
pubmed: 30680676
Eur J Cancer. 2012 Mar;48(5):599-641
pubmed: 22424278
EJNMMI Phys. 2021 Nov 12;8(1):77
pubmed: 34767102
J Natl Cancer Inst. 2019 Jul 1;111(7):719-726
pubmed: 30551196
Surg Oncol Clin N Am. 2015 Jan;24(1):1-17
pubmed: 25444466
Dermatol Ther (Heidelb). 2020 Dec;10(6):1331-1343
pubmed: 32920709
BMC Cancer. 2020 Nov 26;20(1):1157
pubmed: 33243162
BMJ Qual Saf. 2013 Oct;22(10):809-15
pubmed: 24048616
Per Med. 2021 May;18(3):283-294
pubmed: 33825526
Qual Saf Health Care. 2008 Jun;17(3):216-23
pubmed: 18519629
Lancet Gastroenterol Hepatol. 2021 Jan;6(1):17-29
pubmed: 33166497
Cancer. 2008 Apr 1;112(7):1538-46
pubmed: 18260156

Auteurs

Carla Rognoni (C)

Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Bocconi University, Milan, Italy.

Maria Rosa Barcellona (MR)

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy.

Irene Bargellini (I)

Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Maria Grazia Bavetta (MG)

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy.

Marilena Bellò (M)

Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, Italy.

Maurizia Brunetto (M)

Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Patrizia Carucci (P)

Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, Italy.

Roberto Cioni (R)

Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Laura Crocetti (L)

Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Fabio D'Amato (F)

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy.

Mario D'Amico (M)

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy.

Simona Deagostini (S)

Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, Italy.

Désirée Deandreis (D)

Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, Italy.

Paolo De Simone (P)

Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Andrea Doriguzzi (A)

Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, Italy.

Monica Finessi (M)

Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, Italy.

Paolo Fonio (P)

Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, Italy.

Serena Grimaldi (S)

Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, Italy.

Salvatore Ialuna (S)

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy.

Fabio Lagattuta (F)

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy.

Gianluca Masi (G)

Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Antonio Moreci (A)

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy.

Daniele Scalisi (D)

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy.

Roberto Virdone (R)

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy.

Rosanna Tarricone (R)

Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Bocconi University, Milan, Italy.
Department of Policy Analysis and Public Management, Bocconi University, Milan, Italy.

Classifications MeSH